AVNS
Get informed when a big investor buys or sells
+ FollowOvervalued by 46.4% based on the discounted cash flow analysis.
| Market cap | $1.17 Billion |
|---|---|
| Enterprise Value | $1.24 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.46 |
| Beta | 1.58 |
| Outstanding Shares | 46,400,000 |
| P/E Ratio | -16.62 |
|---|---|
| PEG | 73.13 |
| Price to Sales | 1.66 |
| Price to Book Ratio | 1.56 |
| Enterprise Value to Revenue | 1.73 |
| Enterprise Value to EBIT | -16.73 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.18 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 14,500▼ 31.60% |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 96.90%▼ 0.91% |
|---|---|
| Total Invested | $630.73M▲ 23.73% |
| Investors Holding | 253▼ 18.00% |
No data
The most critical committee for healthcare revenue, as it oversees Medicare and Medicaid reimbursement rates, which drive the adoption and pricing of medical devices.
Allocates the specific funds for the FDA, VA, and HHS, determining the actual cash available for government healthcare spending and procurement.
Directly oversees the FDA, which regulates the approval and safety of every medical instrument Avanos manufactures and sells.
Avanos provides pain management and surgical solutions that are critical for military medicine and the Defense Health Agency's procurement through the NDAA.
The VA is a major purchaser of medical supplies and surgical instruments; policy changes and funding levels directly impact procurement for companies like Avanos.